All Oncology News

The OncLive® News page includes the latest in clinical oncology news, including breaking regulatory decisions, clinical trial findings, pivotal and practice-changing data published in academic peer-reviewed journals, and more across solid and hematologic malignancies. Regulatory news includes new drug approvals by the FDA and European Union, priority review and breakthrough therapy designations, and orphan drug and fast track statuses.

New Trial Designs Hope to Enhance Biomarker Discovery

August 3rd 2015

Clinical trial designs are undergoing a dramatic transformation geared toward the discovery and validation of new predictive biomarkers.

Targeting HER2 in NSCLC Remains Work in Progress

August 2nd 2015

Corey Langer, MD, discussed the therapeutic potential for anti-HER2 agents in non–small cell lung cancer in a presentation at the 2015 International Lung Cancer Congress.

Immune Checkpoint Combination Strategies Evolving in NSCLC

August 1st 2015

A number of clinical trials are now assessing PD-1 and PD-L1 inhibitors in combination with chemotherapy, targeted therapies, and radiation therapy in an attempt to further improve outcomes for patients with non–small cell lung cancer.

Translational Advances Deliver Precision Medicine to NSCLC

July 31st 2015

Paul Bunn, MD, discussed the latest translational advances in NSCLC at the 2015 International Lung Cancer Congress.

Explosion in Next-Generation Agents on Horizon in NSCLC

July 31st 2015

Highly effective next-generation therapies are currently in development for patients with oncogene-driven non–small cell lung cancer, specifically those with alterations in EGFR, ALK, ROS1, NTRK, or a variety of other gene.

Neoadjuvant Pertuzumab Regimen Approved in Europe for HER2-Positive Early Breast Cancer

July 31st 2015

The European Commission has approved the combination of pertuzumab, trastuzumab, and chemotherapy as a neoadjuvant therapy for adult patients with HER2-positive, locally advanced, inflammatory, or early stage breast cancer who are at high risk of recurrence.

Researcher Responsible for CLL Breakthroughs Honored by ASH

July 31st 2015

John C. Byrd, MD, discusses receiving the American Society of Hematology's 2015 William Dameshek Prize for his numerous therapeutic breakthroughs in chronic lymphocytic leukemia, his impactful career, and his goals for the future.

Ibrutinib Induces Impressive Response in DLBCL Subtype

July 30th 2015

Ibrutinib had an overall response rate of 37% in patients with activated B-cell-like diffuse large B-cell lymphoma.

Regulatory Approval Sought for Eribulin in Soft Tissue Sarcoma

July 30th 2015

An application has been submitted to the FDA for eribulin mesylate (Halaven) as a treatment for patients with soft tissue sarcoma following an anthracycline and at least one other regimen.

UCLA Jonsson Comprehensive Cancer Center Teams With OncLive as a Strategic Alliance Partner

July 30th 2015

OncLive's editorial and marketing groups will spread the news about the center's community outreach and research programs.

Idelalisib Use Expands With New CLL Indication Pending

July 30th 2015

The utilization of idelalisib increased substantially between the first and second quarters of 2015, representing promising growth in a highly competitive setting.

Novel Radium-223 Combinations on the Horizon in Bone-Metastatic CRPC

July 29th 2015

Novel combination approaches are currently under exploration that hope to capitalize on the varying mechanisms of action for each newly approved agent for men with metastatic castration-resistant prostate cancer.

Gender Disparities and Other DLBCL Developments

July 28th 2015

Tahir Latif, MD, discusses results of a recent study which found that men may have a lower rate of survival among patients with diffuse large B-cell lymphoma.

FDA Grants Breakthrough Designation to Lenvatinib for Renal Cell Carcinoma

July 28th 2015

The FDA has granted a breakthrough therapy designation to lenvatinib as a potential treatment for patients with advanced renal cell carcinoma who have received a VEGF-targeted therapy.

Novel Agents Continue to Transform Lymphoma Treatment

July 27th 2015

Gilles A. Salles, MD, PhD, discussed treatment regimens being developed for follicular lymphoma.

FDA Expands Carfilzomib's Myeloma Approval

July 24th 2015

The FDA has broadened the approval of carfilzomib to include patients with relapsed multiple myeloma who have received at least one prior therapy.

FDA Approves Sonidegib for Basal Cell Carcinoma

July 24th 2015

The FDA has approved sonidegib (Odomzo) for the treatment of patients with locally advanced basal cell carcinoma that has recurred.

Efficacy Maintained, QoL Improved With Radiation Dose Reductions in Oropharyngeal Cancer

July 24th 2015

Barbara Ann Burtness, MD, discusses the impact of two studies examining reductions in radiation and chemotherapy dose in low-risk HPV-associated oropharyngeal cancer.

Pembrolizumab Benefit in SCCHN Confirmed in Expansion Study

July 24th 2015

Tanguy Y. Seiwert, MD, discusses the significance of the expansion results of KEYNOTE-012 for advanced squamous cell carcinoma of the head and neck.

Regulatory Filings Move Dabrafenib/Trametinib Combo Closer to Full Melanoma Approval

July 24th 2015

The FDA has assigned a priority review designation to the combination of dabrafenib and trametinib for patients with unresectable or metastatic BRAFV600 mutation-positive melanoma.